Targeted therapies: Denileukin diftitox--a step towards a 'magic bullet' for CTCL.
Kadin
Marshall E
ME
Vonderheid
Eric C
EC
D000970:Antineoplastic Agents / Q000627:therapeutic use*; D004167:Diphtheria Toxin / Q000276:immunology / Q000627:therapeutic use*; D006801:Humans; D007150:Immunohistochemistry; D007376:Interleukin-2 / Q000627:therapeutic use*; D053645:Interleukin-2 Receptor alpha Subunit / Q000187:drug effects* / Q000276:immunology; D016410:Lymphoma, T-Cell, Cutaneous / Q000188:drug therapy* / Q000276:immunology; D011379:Prognosis; D015375:Receptors, Interleukin-2 / Q000187:drug effects*; D011993:Recombinant Fusion Proteins / Q000627:therapeutic use; D012878:Skin Neoplasms / Q000188:drug therapy* / Q000276:immunology; D050378:T-Lymphocytes, Regulatory
D000970:Antineoplastic Agents; D004167:Diphtheria Toxin; C508017:IL2RA protein, human; D007376:Interleukin-2; D053645:Interleukin-2 Receptor alpha Subunit; D015375:Receptors, Interleukin-2; D011993:Recombinant Fusion Proteins; C078456:denileukin diftitox